Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay

British Journal of Haematology

Volumn 106, Issue 1, 1999, Pages 71-77

  Bosanquet, Andrew G ^a,d   Johnson, Stephen A ^b   Richards, Sue M ^c  

^a UNIVERSITY OF BATH   (United Kingdom)

^b MUSGROVE PARK HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

Chronic lymphocytic leukaemia; Differential staining cytotoxicity assay; Disease management; Fludarabine; Prognosis

Indexed keywords

FLUDARABINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVAL RATE; THERAPEUTICS; VIDARABINE;

EID: 0032838007     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01516.x     Document Type: Article

References (39)

1. Best, L. (1995) Fludarabine in the treatment of chronic lymphocytic leukaemia. Report to the South and West Region Development and Evaluation Committee. Bristol: NHS Executive (South and West).
2. Bird, M.C., Bosanquet, A.G., Forskitt, S. & Gilby, E.D. (1988) Long-term comparison of results of a drug sensitivity assay in vitro with patient response in lymphatic neoplasms. Cancer, 61, 1104-1109.
3. Boddy, A.V. & Ratain, M.J. (1997) Pharmacogenetics in cancer etiology and chemotherapy. Clinical Cancer Research, 3, 1025-1030.
4. Bosanquet, A.G. (1991) Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet, 337, 711-714.
5. Bosanquet, A.G. (1994) Short-term in vitro drug sensitivity tests for cancer chemotherapy: a summary of correlations of test result with both patient response and survival. Forum Trends in Experimental and Clinical Medicine, 4, 179-195.
6. Bosanquet, A.G. (1999) Fludarabine: phosphate or no phosphate, that is the confusion. Clinical Cancer Research, 5, 475-476.
7. Bosanquet, A.G. & Bell, P.B. (1996a) Enhanced ex vivo drug sensitivity testing of chronic lymphocytic leukaemia using refined DiSC assay methodology. Leukaemia Research, 20, 143-153.
8. Bosanquet, A.G. & Bell, P.B. (1996b) Novel ex vivo analysis of nonclassical, pleiotropic drug resistance and collateral sensitivity induced by therapy provides a rationale for treatment strategies in chronic lymphocytic leukemia. Blood, 87, 1962-1971.
9. Bosanquet, A.G., Bell, P.B., Burlton, A.R. & Amos, T.A.S. (1996) Correlation of bcl-2 with P-glycoprotein expression in chronic lymphocytic leukaemia and other haematologic neoplasms but of neither marker with ex vivo chemosensitivity or patient survival. Leukemia and Lymphoma, 24, 141-147.
10. Bosanquet, A.G., Burlton, A.R., Bell, P.B. & Harris, A.L. (1997) Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP. British Journal of Cancer. 76, 511-518.
11. Bosanquet, A.G., Copplestone, J.A., Johnson, S.A.N., Smith, A.G., Povey, S.J., Orchard, J.A. & Oscier, D.G. (1999) Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay, British Journal of Haematology, 106, 474-476.
12. Bosanquet, A.G., McCann, S.R., Crotty, G.M., Mills, M.J. & Catovsky, D. (1995) Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematologica, 93, 73-79.
13. Bowen, A.L., Bosanquet, A.G., Catovsky, D. & Matutes, E. (1999) P53 deletion and fludarabine-resistance in chronic lymphocytic leukaemia. British Journal of Haematology. 105, (Suppl. 1), 85.
14. Bromidge, T.J., Turner, D.L., Howe, D.J., Johnson, S.A. & Rule, S.A. (1998) In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues: correlation with clinical course. Leukemia, 12, 1230-1235.
15. Catovsky, D. (1990) CLL3. Third MRC trial in chronic lymphocytic leukaemia. Clinical Trials Service Unit, Oxford.
16. Catovsky, D., Richards, S., Fooks, J. & Hamblin, T.J. (1991) CLL trials in the United Kingdom: the Medical Research Council CLL trials 1, 2 and 3. Leukemia and Lymphoma, Supplement, 105-112.
17. Debatin, K.-M. (1997) Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. Journal of the National Cancer Institute, 89, 750-751.
18. Dighiero, G., Maloum, K., Desablens, B., Cazin, B., Navarro, M., Leblay, R., Leporrier, M., Jaubert, J., Lepeu, G., Dreylus, B., Binet, J.L. & Travade, P. (1998) Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. New England Journal of Medicine, 338, 1506-1514.
19. Dohner, H., Fisher, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P.R., Poustka, A., Hunstein, W. & Lichter, P. (1995) p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogues in chronic B-cell leukemias. Blood, 85, 1580-1589.
20. Frame, J.N., Dahut, W.L. & Crowley, S. (1992) Fludarabine and acute tumor lysis in chronic lymphocytic leukemia. New England Journal of Medicine, 327, 1396-1397.
21. Fruchauf, J.P. & Bosanquet, A.G. (1993) In vitro determination of drug response: a discussion of clinical applications. Principles and Practice in Oncology Updates, 7 (Dec.), 1-16.
22. Grever, M.R., Kopecky, K.J., Coltman, C.A., Files, J.C., Greenberg, B.R., Hutton, J.J., Talley, R., Von Hoff, D.D. & Balcerzak, S.P. (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouvelle Revue Française d'Hematologie, 30, 457-459.
23. Johnson, S.A., Catovsky, D., Child, J.A., Newland, A.C., Milligan, D.W. & Janmohamed, R. (1998) Phase I/II evaluation of pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory chronic lymphocytic leukaemia. Investigational New Drugs, 16, 155-160.
24. Kaspers, G.J.L., Smets, L.A., Pieters, R., Van Zantwijk, C.H., Van Wering, E.R. & Veerman, A.J.P. (1995) Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood, 85, 751-756.
25. Keating, M.J., Kantarjian, H., O'Brien, S., Koller, C., Talpaz, M., Schachner, J., Childs, C.C., Freireich, E.J. & McCredie, K.B. (1991) Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 9, 44-49.
26. Keating, M.J., Kantarjian, H., Talpaz, M., Redman, J., Koller, C., Barlogie, B., Velasquez, W., Plunkett, W., Freireich, E.J. & McCredie, K.B. (1989) Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 74, 19-25.
27. Klumper, E., Ossenkoppele, G.J., Pieters, R., Huismans, D.R., Loonen, A.H., Rottier, A., Westra, G. & Veerman, A.J.P. (1996) In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. British Journal of Haematology, 93, 903-910.
28. Krammer, P.H. (1997) The tumour strikes back: New data on expression of the CD95 (APO-1/Fas) receptor/ligand system may cause paradigm changes in our view on drug treatment and tumor immunology. Cell Death and Differentiation, 4, 362-364.
29. Mason, J.M., Drummond, M.F., Bosanquet, A.G. & Sheldon, T.A. (1999) The DiSC assay: a cost-effective guide to treatment for chronic lymphocytic leukaemia? International Journal of Technology Assessment in Health Care, 15, 173-184.
30. Morabito, F., Stelitano, C., Callea, I., Dattola, A., Console, G., Pucci, G., Iacopino, P., Callea, V., Di Raimondo, F. & Brugiatelli, M. (1998) In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 102, 528-531.
31. Myint, H., Copplestone, J.A., Orchard, J., Craig, V., Curtis, D., Prentice, A.G., Hamon, M.D., Oscier, D.G. & Hamblin, T.J. (1995) Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 91, 341-344.
32. O'Brien, S., Kantarjian, H., Beran, M., Smith, T., Koller, C., Estey, E., Robertson, L.E., Lerner, S. & Keating, M. (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood, 82, 1695-1700.
33. Rai, K.R., Peterson, B., Elias, L., Shepherd, L., Hines, J., Nelson, D., Cheson, B., Kolitz, J. & Schiffer, C.A. (1996) A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: a CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood, 88, (Suppl. 1), 141a.
34. Richardson, D.S., Johnson, S.A., Hopkins, J.A., Howe, D. & Phillips, M.J. (1994) Absence of minimal residual disease detectable by FACS, Southern Blot or PCR in patients with chronic lymphocytic leukaemia treated with fludarabine. Acta Oncologica, 33, 627-630.
35. Shvidel, L., Shtarlid, M., Klepfish, A., Sigler, E. & Berrebi, A. (1997) Evans syndrome complicating fludarabine treatment for advanced B-CLL. British Journal of Haematology, 99, 706.
36. Sorensen, J.M., Vena, D.A., Fallavollita, A., Chun, H.G. & Cheson, B.D. (1997) Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. Journal of Clinical Oncology, 15, 458-465.
37. Spriano, M., Clavio, M., Carrara, P., Canepa, L., Miglino, M., Pierri, I., Celesti, L., Rossi, E., Vimercati, R., Bruni, R., Santini, G., Gatti, A.M., Stura, P., Ghio, R., Patrone, F., Damasio, E. & Gobbi, M. (1994) Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica, 79, 218-226.
38. The French Cooperative Group on CLL. Johnson, S., Smith, A.G., Löffler, H., Ösby, E., Juliusson, G., Emmerich, B., Wyld, P.J. & Hiddemann, W. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet, 347, 1432-1438.
39. Williamson, L.M., Wimperis, J.Z., Wood, M.E. & Woodcock, B. (1996) Fludarabine treatment and transfusion-associated graft-versus-host disease. Lancet, 348, 472-473.